Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
ADVAXIS RG (NQ: ADXS)
1.640 USD  -0.050 (-2.96%)
Official Closing Price  /  Updated: 8:00 PM EDT, Apr 20, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 319,077
Open 1.680
Bid (Size) 1.620 (200)
Ask (Size) 1.860 (2500)
Prev. Close 1.690
Today's Range 1.640 - 1.712
52wk Range 1.510 - 9.550
Shares Outstanding 52,313,849
Dividend Yield N/A
Performance
YTD
-47.10%
-47.10%
1 Month
-12.30%
-12.30%
3 Month
-45.51%
-45.51%
6 Month
-53.14%
-53.14%
1 Year
-79.80%
-79.80%
Top News
More News
Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-HOT... Read More
from Business Wire News Releases
Data Highlighting Advaxis’ ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that The American Society of Clinical... Read More
from Business Wire News Releases
More News
Read More
Upbeat jobless data lifts markets
category Market News
from MarketMinute.com Market Updates
Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018
from Business Wire News Releases
Advaxis prices offering at discount
from MarketMinute.com Stock News
Technical Perspectives on Biotech Stocks -- 22nd Century, Abeona Therapeutics, Advaxis, and Adverum Biotechnologies
from PR Newswire
Advaxis to Present at Upcoming March Conferences
from Business Wire News Releases
Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)
from Business Wire News Releases
Advaxis to Host Business Update and First Quarter 2018 Financial Results Conference Call on March 12, 2018
from Business Wire News Releases
5 Biggest Price Target Changes For Wednesday
category NTNX , Price Target , Intraday Update , and 7 more.
from Benzinga
Mid-Afternoon Market Update: Commercial Vehicle Group Falls Following Q4 Results; Bovie Medical Shares Surge
category DKS , Eurozone , News , and 14 more.
from Benzinga
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial